|Bid||63.32 x 100|
|Ask||64.83 x 100|
|Day's Range||63.69 - 64.69|
|52 Week Range||46.01 - 66.10|
|PE Ratio (TTM)||23.28|
|Earnings Date||Oct 26, 2017|
|Dividend & Yield||1.56 (2.42%)|
|1y Target Est||60.68|
Bristol-Myers' (BMY) Opdivo is expected to generate increased revenues following its label expansion in the third quarter of 2017. Approval of Orencia in psoriatic arthritis is also a positive.
The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
Bristol-Myers Squibb Company today announced that new data across serious liver diseases, including nonalcoholic steatohepatitis and hepatocellular carcinoma , will be presented at The Liver Meeting® 2017 in Washington, DC, October 20 – 24, 2017.
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
Bristol-Myers Squibb (BMY) has a portfolio that includes cardiovascular, oncology, neuroscience, immuno-science, and virology drugs.
Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration has accepted for priority review its supplemental Biologics License Application for Opdivo to treat patients with melanoma who are at high risk of disease recurrence following complete surgical resection.
Is it time to get cautious on Bristol-Myers Squibb (BMY). The drug maker’s share price is falling today after Jefferies analyst Jeffrey Holford downgraded the stock from a Buy to a Hold, and shaved his 12-month price target by a dollar to $71 a share. Sure, Holford sees Bristol-Myers as a leading player in the immuno-oncology market and believes that the Street may be underestimating the potential for some of its drugs, namely the diverse set of indications it is pursuing for the cancer drug cocktail composed of Opdivo and Yervoy.
Stocks look set for a higher open this morning after the Dow and S&P closed just below new highs last week. S&P 500 futures have ticked up 0.1%, while Dow Jones Industrial Average futures have advanced ...
Bristol-Myers Squibb (BMY: NYSE) Guggenheim Securities ($65.11, Oct. 12, 2017) We are raising our price target for Bristol-Myers Squibb to $75 from $68. Our ...
LONDON, UK / ACCESSWIRE / October 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Bristol-Myers Squibb Co. (NYSE: BMY ), following which we have ...
Bristol-Myers Squibb Company today announced data evaluating Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer patients whose tumors were evaluable for tumor mutation burden , from the Phase 1/2 CheckMate -032 trial.
CHAPEL HILL, N.C , Oct. 12, 2017 /PRNewswire/ -- TARGET PharmaSolutions, Inc., a real-world clinical data company, is pleased to announce that Bristol-Myers Squibb (BMY) has extended its strategic partnership ...
Bristol-Myers Squibb Company announced that it has appointed scientific and business thought-leader, Saurabh Saha, M.D., Ph.D., as senior vice president and global head of translational medicine in the company’s R&D organization, effective today.
Bristol-Myers Squibb Company , in collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association, a leading liver cancer patient advocacy organization, today announced the findings from a new survey exploring the experiences of caregivers of people living with early or advanced stage liver cancer in the U.S.
Bristol-Myers Squibb (BMY), a US pharmaceutical company, includes innovative products from its Cardiovascular, Immunoscience, Neuroscience, Oncology, and Virology franchises.
Bristol-Myers Squibb’s (BMY) Immunoscience franchise includes Orencia, which is a fusion protein used for the treatment of rheumatoid arthritis and aligned problems.